1. Home
  2. MYFW vs EDIT Comparison

MYFW vs EDIT Comparison

Compare MYFW & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

MYFW

First Western Financial Inc.

HOLD

Current Price

$26.15

Market Cap

220.8M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.36

Market Cap

233.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MYFW
EDIT
Founded
2002
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
220.8M
233.3M
IPO Year
2018
2016

Fundamental Metrics

Financial Performance
Metric
MYFW
EDIT
Price
$26.15
$2.36
Analyst Decision
Buy
Strong Buy
Analyst Count
2
4
Target Price
$24.25
$4.50
AVG Volume (30 Days)
31.3K
1.7M
Earning Date
01-22-2026
11-10-2025
Dividend Yield
N/A
N/A
EPS Growth
391.62
N/A
EPS
1.28
N/A
Revenue
$95,514,000.00
$46,383,000.00
Revenue This Year
$15.96
N/A
Revenue Next Year
$13.77
N/A
P/E Ratio
$20.41
N/A
Revenue Growth
19.92
N/A
52 Week Low
$17.10
$0.91
52 Week High
$26.40
$4.54

Technical Indicators

Market Signals
Indicator
MYFW
EDIT
Relative Strength Index (RSI) 73.24 41.37
Support Level $25.20 $2.33
Resistance Level $26.40 $2.61
Average True Range (ATR) 0.58 0.18
MACD 0.11 0.02
Stochastic Oscillator 90.67 43.44

Price Performance

Historical Comparison
MYFW
EDIT

About MYFW First Western Financial Inc.

First Western Financial Inc is a financial holding company that provides a fully integrated suite of wealth management services on its private trust bank platform, which includes a comprehensive selection of deposit, loan, trust, wealth planning, and investment management products and services. The company has two operating segments; The Wealth Management segment consists of operations relative to the Company's fully integrated wealth management products and services, and The Mortgage segment consists of operations relative to the Company's residential mortgage service offerings. The bank derives its majority revenue from the wealth management segment.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.

Share on Social Networks: